<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5254">
  <stage>Registered</stage>
  <submitdate>18/06/2014</submitdate>
  <approvaldate>18/06/2014</approvaldate>
  <nctid>NCT02170090</nctid>
  <trial_identification>
    <studytitle>Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer</studytitle>
    <scientifictitle>Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)</scientifictitle>
    <utrn />
    <trialacronym>ACTICCA-1</trialacronym>
    <secondaryid>2012-005078-70</secondaryid>
    <secondaryid>ACTICCA-1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cholangiocarcinoma</healthcondition>
    <healthcondition>Gall Bladder Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Biliary tree (gall bladder and bile duct)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Gemcitabine
Treatment: drugs - Cisplatin
Treatment: drugs - Capecitabine

Experimental: Gemcitabine plus Cisplatin - Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter)
and Observation

Active Comparator: Capecitabine - Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily)
and Observation


Treatment: drugs: Gemcitabine
Gemcitabine 1000mg/m2

Treatment: drugs: Cisplatin
Cisplatin 25mg/m2

Treatment: drugs: Capecitabine
Capecitabine 1250mg/m2

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease free survival (DFS) - DFS</outcome>
      <timepoint>Disease free survival rate at 24 months (DFSR@24)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease free survival rate at 24 months (DFSR@24) - DSFR</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Recurrence free survival - RFS</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - OS</outcome>
      <timepoint>84 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability (assessed by the rate of patients with adverse events according to NCI CTC AE v4.03)</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life - QOL</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Function of biliodigestive anastomosis (in terms of surgical revision, requirement for PTCD)</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate and severity of biliary tract infections</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of disease recurrence</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence)</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All enrolled patients will postoperatively be assessed for eligibility for the treatment
        phase. Additionally patients not previously enrolled into the trial for whatever reason
        (e.g. incidental finding during surgery) will be evaluated for eligibility.

          -  Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or
             extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after
             radical surgical therapy with macroscopically complete resection (mixed tumor entities
             (HCC/CCA) are excluded)

          -  Macroscopically complete resection (R0/1) within 6 (-16) weeks before scheduled start
             of chemotherapy

          -  ECOG 0-1

          -  Age =18 years

          -  Adequate hematologic function

          -  Adequate liver function

          -  Adequate renal function

          -  No active uncontrolled infection, except chronic viral hepatitis under antiviral
             therapy

          -  No concurrent treatment with other experimental drugs or other anti-cancer therapy,
             treatment in a clinical trial within 30 days prior to randomization

          -  Negative serum pregnancy test within 7 days of starting study treatment in
             pre-menopausal women and women &lt;1 year after the onset of menopause (Note: a negative
             test has to be reconfirmed by a urine test, should the 7-day window be exceeded)

        Criteria for initial study enrolment

          -  Written informed consent

          -  No prior chemotherapy for cholangiocarcinoma

          -  No previous malignancy within 3 years or concomitant malignancy, except:
             non-melanomatous skin cancer or adequately treated in situ cervical cancer

          -  No severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction in the last 3 months,
             significant arrhythmia)

          -  Absence of psychiatric disorder precluding understanding of information of trial
             related topics and giving informed consent

          -  No serious underlying medical conditions (judged by the investigator), that could
             impair the ability of the patient to participate in the trial

          -  Fertile women (&lt; 1 year after last menstruation) and procreative men willing and able
             to use effective means of contraception (oral contraceptives, intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly or surgically sterile)

          -  No pregnancy or lactation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>781</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA</recruitmentstate>
    <hospital>Bankstown Hospital - Bankstown</hospital>
    <hospital>Nepean Hospital Cancer Care - Kingswood</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Townsville Hospital - Douglas</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode> - Bankstown</postcode>
    <postcode> - Kingswood</postcode>
    <postcode> - St Leonards</postcode>
    <postcode> - Waratah</postcode>
    <postcode> - Douglas</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Vejle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bournemouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Great Yarmouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Huddersfield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Maidstone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Universitätsklinikum Hamburg-Eppendorf</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Deutsche Krebshilfe e.V., Bonn (Germany)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>medac GmbH</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Research UK</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Gastro Intestinal Trials Group (AGITG)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>KWF Kankerbestrijding The Netherlands</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicentre, two stage, prospective, randomized, controlled phase III trial
      designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
      standard of care (capecitabine) and observation in patients after curative intent resection
      of cholangiocarcinoma and muscle invasive gall bladder carcinoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02170090</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Henning Wege</name>
      <address>Universitätsklinikum Hamburg-Eppendorf</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Alexander Stein</name>
      <address />
      <phone>004940741056882</phone>
      <fax />
      <email>a.stein@uke.de</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>